vs
Amphastar Pharmaceuticals, Inc.（AMPH）とApellis Pharmaceuticals, Inc.（APLS）の財務データ比較。上の社名をクリックして会社を切り替えられます
Apellis Pharmaceuticals, Inc.の直近四半期売上が大きい（$199.9M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.1倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs -29.5%、差は42.8%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -5.9%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $-14.3M）。過去8四半期でApellis Pharmaceuticals, Inc.の売上複合成長率が高い（7.7% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
アペリスファーマシューティカルズは補体系を調節する標的治療薬の開発に注力する臨床段階のバイオ医薬品企業です。加齢黄斑変性に続発する地図状萎縮をはじめとする眼科疾患、希少血液疾患、自己免疫疾患を主な適応とし、米国と欧州を中心に事業を展開しています。
AMPH vs APLS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $199.9M |
| 純利益 | $24.4M | $-59.0M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | -25.6% |
| 純利益率 | 13.3% | -29.5% |
| 売上前年比 | -1.8% | -5.9% |
| 純利益前年比 | -35.7% | -62.2% |
| EPS（希薄化後） | $0.51 | $-0.40 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $199.9M | ||
| Q3 25 | $191.8M | $458.6M | ||
| Q2 25 | $174.4M | $178.5M | ||
| Q1 25 | $170.5M | $166.8M | ||
| Q4 24 | $186.5M | $212.5M | ||
| Q3 24 | $191.2M | $196.8M | ||
| Q2 24 | $182.4M | $199.7M | ||
| Q1 24 | $171.8M | $172.3M |
| Q4 25 | $24.4M | $-59.0M | ||
| Q3 25 | $17.4M | $215.7M | ||
| Q2 25 | $31.0M | $-42.2M | ||
| Q1 25 | $25.3M | $-92.2M | ||
| Q4 24 | $38.0M | $-36.4M | ||
| Q3 24 | $40.4M | $-57.4M | ||
| Q2 24 | $37.9M | $-37.7M | ||
| Q1 24 | $43.2M | $-66.4M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -25.6% | ||
| Q3 25 | 13.2% | 48.7% | ||
| Q2 25 | 24.2% | -18.6% | ||
| Q1 25 | 21.9% | -50.0% | ||
| Q4 24 | 24.2% | -12.3% | ||
| Q3 24 | 29.8% | -24.0% | ||
| Q2 24 | 30.3% | -14.7% | ||
| Q1 24 | 27.9% | -36.0% |
| Q4 25 | 13.3% | -29.5% | ||
| Q3 25 | 9.0% | 47.0% | ||
| Q2 25 | 17.8% | -23.6% | ||
| Q1 25 | 14.8% | -55.3% | ||
| Q4 24 | 20.4% | -17.1% | ||
| Q3 24 | 21.1% | -29.2% | ||
| Q2 24 | 20.8% | -18.9% | ||
| Q1 24 | 25.1% | -38.5% |
| Q4 25 | $0.51 | $-0.40 | ||
| Q3 25 | $0.37 | $1.67 | ||
| Q2 25 | $0.64 | $-0.33 | ||
| Q1 25 | $0.51 | $-0.74 | ||
| Q4 24 | $0.74 | $-0.30 | ||
| Q3 24 | $0.78 | $-0.46 | ||
| Q2 24 | $0.73 | $-0.30 | ||
| Q1 24 | $0.81 | $-0.54 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $466.2M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $370.1M |
| 総資産 | $1.6B | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $466.2M | ||
| Q3 25 | $276.2M | $479.2M | ||
| Q2 25 | $231.8M | $370.0M | ||
| Q1 25 | $236.9M | $358.4M | ||
| Q4 24 | $221.6M | $411.3M | ||
| Q3 24 | $250.5M | $396.9M | ||
| Q2 24 | $217.8M | $360.1M | ||
| Q1 24 | $289.6M | $325.9M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | $93.1M |
| Q4 25 | $788.8M | $370.1M | ||
| Q3 25 | $776.7M | $401.2M | ||
| Q2 25 | $757.5M | $156.3M | ||
| Q1 25 | $751.3M | $164.2M | ||
| Q4 24 | $732.3M | $228.5M | ||
| Q3 24 | $727.7M | $237.1M | ||
| Q2 24 | $713.3M | $264.3M | ||
| Q1 24 | $672.4M | $266.7M |
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.6B | $821.4M | ||
| Q1 25 | $1.6B | $807.3M | ||
| Q4 24 | $1.6B | $885.1M | ||
| Q3 24 | $1.5B | $901.9M | ||
| Q2 24 | $1.5B | $904.5M | ||
| Q1 24 | $1.6B | $831.9M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | 0.35× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $-14.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-14.3M |
| FCFマージンFCF / 売上 | 13.4% | -7.1% |
| 設備投資強度設備投資 / 売上 | 4.5% | 0.1% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $45.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $-14.2M | ||
| Q3 25 | $52.6M | $108.5M | ||
| Q2 25 | $35.6M | $4.4M | ||
| Q1 25 | $35.1M | $-53.4M | ||
| Q4 24 | $29.0M | $19.4M | ||
| Q3 24 | $60.0M | $34.1M | ||
| Q2 24 | $69.1M | $-8.3M | ||
| Q1 24 | $55.3M | $-133.0M |
| Q4 25 | $24.6M | $-14.3M | ||
| Q3 25 | $47.2M | $108.3M | ||
| Q2 25 | $25.0M | $4.4M | ||
| Q1 25 | $24.4M | $-53.4M | ||
| Q4 24 | $16.6M | $19.3M | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | $-8.4M | ||
| Q1 24 | $46.5M | $-133.3M |
| Q4 25 | 13.4% | -7.1% | ||
| Q3 25 | 24.6% | 23.6% | ||
| Q2 25 | 14.3% | 2.5% | ||
| Q1 25 | 14.3% | -32.0% | ||
| Q4 24 | 8.9% | 9.1% | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | -4.2% | ||
| Q1 24 | 27.1% | -77.3% |
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 6.3% | 0.0% | ||
| Q4 24 | 6.7% | 0.0% | ||
| Q3 24 | 7.2% | 0.0% | ||
| Q2 24 | 3.3% | 0.0% | ||
| Q1 24 | 5.1% | 0.2% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 0.50× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
